| apixaban versus aspirin | |||
| AVERROES, 2011 NCT00496769 | apixaban 5 mg (or 2.5 mg) twice daily versus aspirin 81-324 md daily | patients with atrial fibrillation who have failed or are unsuitable for vitamin K antagonist treatment | double blind Follow-up duration: maximum 21 months 36 countries |
| apixaban versus warfarin standard dose | |||
| ARISTOTLE, 2011 NCT00412984 | apixaban 5mg twice daily
versus warfarin adjusted for an INR between 2 and 3 | subjects with atrial fibrillation and risk factors for stroke | double blind Follow-up duration: 1.8 yrs (median) 39 countries |
| phase 2 apixaban, 0 NCT00787150 | apixaban 5 or 2.5 mg twice daily versus warfarin | patient with non valvular AF | double blind Follow-up duration: 12 weeks |
| aspirin versus control | |||
| Japanese AF Trial, 2006 | aspirin at 150 to 200 mg per day versus no antiplatelet or anticoagulant therapy | patients with nonvalvular atrial fibrillation | |
| LASAF(aspirin vs no treatment), 1999 | aspirin:125mg/day(group A1);125mg on alternate days(group A2)
versus no control treatment(group C) | Open | |
| aspirin versus coumadin low dose | |||
| PATAF (vs coumadin low dose), 1999 | aspirin 300mg/d versus coumarin low dose(target INR 1.1-1.6 ) | non rheumatic AF,recruited in general practice,with no established indication for anticoagulation. | Simple aveugle Follow-up duration: 2.7 years Netherlands |
| aspirin versus coumadin standard dose | |||
| PATAF (vs coumadin standard dose), 1999 | aspirin 150mg/d versus coumarin standard dose(target INR 2.5-3.5) | non rheumatic AF,recruited in general practice,with no established indication for anticoagulation. | Simple aveugle Follow-up duration: 2.7 years Netherlands |
| aspirin versus placebo | |||
| AFASAK (aspirin vs placebo), 1989 | aspirin 75 mg/d
versus placebo | patients with chronic non-rheumatic atrial fibrillation | Double aveugle Follow-up duration: 2 years Denmark |
| SPAF (aspirin , warfarin eligible arm), 1991 | aspirin 325mg/d
versus placebo | nonrheumatic atrial fibrillation,warfarin eligible patients | Double blind Follow-up duration: 1.3 years USA |
| SPAF (aspirin,warfarin ineligible arm), 1991 | aspirin 325mg/d
versus placebo | nonrheumatic atrial fibrillation, warfarin ineligible patients | Double blind Follow-up duration: 1.3 years USA |
| aspirin versus warfarin low dose | |||
| AFASAK II (aspirin vs warfarin low dose), 1998 | aspirin 300 mg/d versus warfarin low dose (1.25mg/d) | chronic non valvular atrial fibrillation | Open Follow-up duration: 3.5 years Denmark |
| aspirin versus warfarin standard dose | |||
| AFASAK (aspirin vs warfarin standard dose), 1989 | aspirin (low dose 75 mg) versus warfarin standard dose(target INR 2.8-4.2) | chronic non rheumatic AF | Open Follow-up duration: 2 years Denmark |
| AFASAK II (aspirin vs warfarin standard dose), 1998 | aspirin 300 mg/d versus warfarin standard dose(target INR 2-3) | chronic non valvular atrial fibrillation | Open Follow-up duration: 3.5 years Denmark |
| SPAF II (aspirin vs warfarin standard dose, age<75), 1994 | aspirin 325 mg/d versus warfarin standard dose(target INR 2.0-4.5) | non rheumatic atrial fibrillation,medium to high risk patients. Patients aged 75 and less. | Open Follow-up duration: 3.1 years USA |
| SPAF II (aspirin vs warfarin standard dose, age>75), 1994 | aspirin 325 mg/d versus warfarin standard dose (target INR 2.0-4.5) | Non rheumatic atrial fibrillation,medium to high risk patients.Patients aged more than 75. | Open Follow-up duration: 2.0 years USA |
| aspirin + clopidogrel versus anticoagulant | |||
| ACTIVE W, 2006 NCT00243178 | clopidogrel (75 mg per day) plus aspirin (75–100 mg per day) versus oral anticoagulation therapy (target international normalised ratio of 2·0–3·0) | Patients with atrial fibrillation plus one or more risk factor for stroke | open Follow-up duration: 1.28 y (median) |
| aspirin + clopidogrel versus aspirin | |||
| ACTIVE A, 2009 NCT00249873 | clopidogrel 75 mg daily + aspirin 75-100 mg daily versus aspirin 75-100 mg daily alone | Patients with AF and at least one risk factor for stroke and who are not candidates for warfarin therapy | double blind Follow-up duration: 3.7 y |
| AZD0837 versus aspirin | |||
| phase 2 AZD0837, 0 NCT00623779 | AZD0837 versus aspirin | patients with atrial fibrillation, who are appropriate for but unable or unwilling to take Vitamin-K antagonist(VKA) therapy | open |
| AZD0837 versus warfarin standard dose | |||
| Lip (phase 2 AZD0837), 2009 NCT00684307 | AZD0837 for 3-9 months versus dose-adjusted Vitamin-K antagonists (VKA) (aiming for an international normalized ratio (INR) 2.0 to 3.0) | patients with non-valvular atrial fibrillation (AF) with one or more additional risk factors for stroke | double blind Follow-up duration: 3 or 9 months |
| coumadin low dose versus coumadin standard dose | |||
| PATAF (coumadin low dose vs coumadin standard dose), 1999 | coumarin low dose(target INR 1.1-1.6) versus coumarin standard dose(target INR 2.5-3.5) | non rheumatic AF,recruited in general practice,with no established indication for anticoagulation. | Simple aveugle Follow-up duration: 2.7 years Netherlands |
| dabigatran versus warfarin standard dose | |||
| phase 2 dabigatran, 0 NCT01136408 | Dabigatran 110, 220, 300 mg twice daily versus warfarin | patients with non-valvular atrial fibrillation (paroxysmal, persistent or permanent) | open Japan |
| dabigatran 110mg versus warfarin standard dose | |||
| RE-LY (110mg), 2009 NCT00262600 | dabigatran 110 mg twice a day
versus warfarin adjusted dose to a 2-3 INR | Patients With Non-Valvular Atrial Fibrillation | open (blind assessment) Follow-up duration: 2 y (median) 44 countries |
| dabigatran 150mg versus warfarin standard dose | |||
| PETRO (150mg), 2007 | dabigatran
150 mg twice daily (alone or combined with 81- or 325-mg aspirin) versus warfarin administered to achieve an international normalized ratio of 2 to 3 for | patients with AF at high risk for thromboembolic events | double blind Follow-up duration: 12 weeks Denmark, The netehrlands, Sweden, US |
| RE-LY (150mg), 2009 NCT00262600 | dabigatran 150 mg twice a day versus warfarin adjusted-dose to a 2.0 to 3.0 INR | Patients With Non-Valvular Atrial Fibrillation | open (blind assessment) Follow-up duration: 2 y (median) 44 countries |
| edoxaban versus warfarin standard dose | |||
| Weitz (edoxaban phase 2), 0 NCT00504556 | Four Fixed Dose Regimens of edoxaban (DU-176b) versus warfarin | Subjects With Non- Valvular Atrial Fibrillation | double-blind Follow-up duration: 3 months USA, Europe, South and central america, |
| phase 2 edoxaban, 0 NCT00806624 | edoxaban (DU-176b) versus warfarin | male and female subjects aged 18 to 80 years, inclusive, with non-valvular AF and a CHADS2 Score of at least 1 | double-blind China |
| edoxaban high dose versus warfarin standard dose | |||
| ENGAGE-AF TIMI 48 High dose, 2013 NCT00781391 | edoxaban 60mg once daily versus warfarin (INR 2-3) | AF patients (CHADS2 >=2) | double blind Follow-up duration: 2.8 years 46 countries |
| edoxaban low dose versus warfarin standard dose | |||
| ENGAGE-AF TIMI 48 Low dose, 2013 NCT00781391 | edoxaban xxx once daily
versus warfarin (INR 2-3) | AF patients (CHADS2 >=2) | double blind Follow-up duration: 2.8 years 46 countries |
| idraparinux versus warfarin standard dose | |||
| AMADEUS, 2008 NCT00070655 | subcutaneous idraparinux 2·5 mg weekly versus adjusted-dose vitamin K antagonists (target of an international normalised ratio of 2–3) | patients with atrial fi brillation at risk for thromboembolism | open Follow-up duration: 10.7 months |
| rivaroxaban versus warfarin standard dose | |||
| ROCKET-AF, 2010 NCT00403767 | Rivaroxaban 20mg p.o. once daily versus Warfarin p.o. once daily titrated to a target INR of 2.5 (range 2.0 to 3.0, inclusive) | Subjects With Non-Valvular Atrial Fibrillation | double blind Follow-up duration: median 1.94 y 45 countries |
| triflusal versus coumadin standard dose | |||
| NASPEAF (triflusal vs coumadin standard dose)), 2004 | Triflusal 600 mg/d versus coumadin standard dose(target INR 2-3) | Non valvular atrial fibrillation. Intermediate risk patients. | Open Follow-up duration: 2.76 years Spain |
| triflusal+coumadin medium dose versus coumadin standard dose | |||
| NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 | Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus coumadin standard dose(target INR 2-3) | Non valvular atrial fibrillation. Intermediate risk patients. | Open Follow-up duration: 2.76 years Spain |
| triflusal+coumadin medium dose versus triflusal | |||
| NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 | Triflusal 600 mg/d + coumadin medium dose (target INR 1.25-2) versus Triflusal 600 mg/d | Non valvular atrial fibrillation. Intermediate risk patients | Open Follow-up duration: 2.76 years Spain |
| warfarin + aspirin versus warfarin standard dose | |||
| AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998 | warfarin fixed low dose(1.25mg/d) + aspirin(300mg/d) versus warfarin standard dose(target INR 2.0-3.0) | chronic non valvular atrial fibrillation | Open Follow-up duration: 3.5 years Denmark |
| SPAF III, 1996 | warfarin low dose(target INR 1.2-1.5)+ aspirin 325 mg/d versus warfarin standard dose(target INR 2.0-3.0) | non rheumatic atrial fibrillation,patients with at least one additional thromboembolic risk factor(high risk patients) | Open Follow-up duration: 1.1 years USA,Canada |
| warfarin low dose versus control | |||
| BAATAF (warfarin vs no treatment), 1990 NCT00000517 | warfarin low dose (target INR:1.5-2.7) versus no placebo.people received no treatment but could choose to take aspirin. | non rheumatic AF | Open Follow-up duration: 2.2 years |
| warfarin low dose versus placebo | |||
| SPINAF (warfarin vs placebo), 1992 | warfarin low dose(target INR 1.4-2.8) versus placebo | men ,with chronic nonrheumatic atrial fibrillation | Double blind Follow-up duration: 1.75 years usa |
| warfarin low dose versus warfarin standard dose | |||
| AFASAK II (warfarin low dose vs warfarin standard dose), 1998 | warfarin fixed low dose (1.25 mg/d) versus warfarin standard dose(target INR 2-3) | chronic non valvular atrial fibrillation | Open Follow-up duration: 3.5 years Denmark |
| MWNAF, 1998 | warfarin low dose (1.25mg/d) versus warfarin standard dose( target INR 2.0-3.0) | Patients over 60 with non rheumatic atrial fibrillation | Open Follow-up duration: 14.5 months Italy |
| warfarin low dose + aspirin versus control | |||
| SAFT(warfarin low dose + aspirin vs no treatment), 2003 | warfarin low dose (1.25 mg/d) + aspirin 75 mg/d versus no treatment | Low-medium risk patients with non valvular atrial fibrillation. | Open Follow-up duration: 33 months Sweden |
| warfarin standard dose versus control | |||
| AFASAK (warfarin standard dose vs control), 1989 | warfarin standard dose(target INR:2.8-4.2) versus control | chronic non rheumatic AF | Open Follow-up duration: 2 years Denmark |
| SPAF (warfarin standard dose), 1991 | warfarin standard dose(target INR:2.0-4.5) versus control | Open Follow-up duration: 1.3 years USA | |
| warfarin standard dose versus placebo | |||
| CAFA, 1991 | warfarin standard dose (target INR 2-3) versus placebo | non rheumatic atrial fibrillation | Double blind Follow-up duration: 15.2 months canada |
| ximelagatran versus warfarin standard dose | |||
| SPORTIF V, 2005 | ximelegatran 36 mg twice daily versus warfarin standard dose(target INR 2-3) | One or more stroke risk factor in addition to atrial fibrillation.High risk patients with non valvular atrial fibrillation. | Double blind Follow-up duration: 20 months north america |
| SPORTIF II (ximelagatran vs warfarin standard dose), 2002 | ximelegatran 20,40,60 mg twice daily versus warfarin standard dose(target INR 2-3) | Medium to high risk patients with chronic non valvular atrial fibrillation. | Open Follow-up duration: 16 weeks Europe ,USA |
| SPORTIF III, 2003 | ximelagatran 36 mg twice daily versus warfarin standard dose (target INR 2-3) | One or more stroke risk factor in addition to AF.High risk patients with non valvular atrial fibrillation. | Open Follow-up duration: 17.4 months europe,asia,australasia |
| YM150 versus warfarin standard dose | |||
| phase 2 YM150, 0 NCT00448214 | YM150 ASTELLAS versus warfarin | subjects with non-valvular atrial fibrillation | open Australia |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
